ArticleCureus2025
Addressing Stroke Care: Overcoming Contrast-Allergy Challenges With Rapid Intravenous Dye Preparation.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypersensitivity reactions to iodinated contrast pose a challenge when urgent neuroimaging is needed in acute stroke. Limited protocols exist for high-risk patients in emergent settings. PURPOSE: To evaluate the safety and efficacy of an emergent intravenous (IV) dye preparation protocol for stroke-alert patients with known contrast allergies, enabling timely neuroimaging. METHODOLOGY: This retrospective study reviewed stroke-alert patients from 2021 to 2023 at a comprehensive stroke center. Patients with documented IV dye allergies but no history of airway edema or anaphylaxis were included. An emergent IV dye preparation protocol was administered, consisting of diphenhydramine 50 mg IV, famotidine 20 mg IV, and dexamethasone 10 mg IV before contrast CT angiography (CTA) or CT perfusion (CTP). Data analysis included descriptive statistics, and statistical significance was determined using chi-square tests, with a
resultsOf 1,001 stroke-alert patients, 58 (5.8%) had a contrast allergy. Twenty-five of these (43%) received emergent contrast imaging; 16 (64%) were female, with a mean age of 66 ± 15 years. Six of 25 (24%) had a large vessel occlusion or severe carotid stenosis detected by CTA/CTP, compared to two of 26 (7.7%) in the non-contrast group (attributable risk 0.16; 95% confidence interval (CI) -0.07 to 0.39;
conclusionsThe emergent IV dye preparation protocol was safe, enabled timely imaging, and improved detection of treatable large-vessel occlusions in acute stroke patients with contrast allergies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.